Drugging ACAT1 for Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Mitochondrial acetyl-CoA acetyltransferase 1 (ACAT1) plays a role in cellular metabolism.
• Aberrant glycolysis is a hallmark of cancer cells, often driven by oncogenic signaling pathways.

Purpose of the Study:

• To investigate the role of oncogenic tyrosine kinases in regulating ACAT1.
• To explore the potential of targeting ACAT1 for anti-cancer therapy.

Main Methods:

• Phosphorylation assays to determine ACAT1 stabilization by tyrosine kinases.
• Glycolysis measurements in cancer cells.
• Screening for small molecule inhibitors of ACAT1.
• In vitro and in vivo anti-cancer efficacy studies.

Main Results:

• Oncogenic tyrosine kinases phosphorylate and stabilize the tetrameric form of ACAT1.
• ACAT1 stabilization by kinases enhances glycolysis in cancer cells.
• A novel small molecule inhibitor of ACAT1 was identified.
• This ACAT1 inhibitor demonstrated significant anti-cancer effects.

Conclusions:

• Oncogenic tyrosine kinases promote cancer cell glycolysis through ACAT1 stabilization.
• Targeting ACAT1 with small molecule inhibitors represents a potential therapeutic strategy for cancer treatment.